Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis.

S. Odes, H. Vardi, M. Friger, D. Esser, F. Wolters, B. Moum, H. Waters, M. Elkjaer, T. Bernklev, E. Tsianos, C. O'Morain, R. Stockbrugger, P. Munkholm, E. Langholz

    Research output: Contribution to journalArticleAcademicpeer-review

    Abstract

    SUMMARY Background Forecasting clinical and economic outcomes in ulcerative colitis (UC) and Crohn's disease (CD) patients is complex but necessary. Aim To determine: (1) frequency of treatment-classified clinical states, (2) probability of transition between states, (3) economic outcomes. Methods Newly diagnosed UC and CD patients, allocated into seven clinical states by medical and surgical treatments recorded in serial 3-month cycles, underwent Markov analysis. Results Over 10 years, 630 UC and 318 CD patients had 22,823 and 11,871 cycles. The most frequent clinical outcomes were medical/surgical remission (medication-free) and mild disease (on 5-aminosalicylates, antibiotics, topical corticosteroids), comprising 28% and 62% of UC cycles respectively; 24% and 51% of CD cycles. The probability of drug-response in patients receiving systemic corticosteroids/immunomodulators was 0.74 in UC, 0.66 in CD. Both diseases had similar likelihood of persistent drug-dependency or drug-refractoriness. Surgery was more probable in CD, 0.20, than UC, 0.08. Apropos economic outcomes, surgery was costlier in UC per cycle, but the outlay over 10 years was greater in CD. Drug-refractory UC and CD cases engendered high costs in the cohort. Conclusions Most patients on 5-aminosalicylates, corticosteroids and immunomodulators had favourable clinical and economic outcomes over 10 years. Drug-refractory and surgical patients exhibited greater long-term expenses.
    Original languageEnglish
    Pages (from-to)735-744
    Number of pages10
    JournalAlimentary Pharmacology & Therapeutics
    Volume31
    Issue number7
    DOIs
    Publication statusPublished - 1 Apr 2010

    Keywords

    • INFLAMMATORY-BOWEL-DISEASE
    • EVIDENCE-BASED CONSENSUS
    • COST
    • MANAGEMENT
    • DIAGNOSIS
    • NORTH
    • MORTALITY
    • RATES
    • SOUTH
    • CARE

    Cite this